{"id":"W2129638180","doi":"10.1200/jco.2007.12.3083","title":"Phase II Study of Vandetanib or Placebo in Small-Cell Lung Cancer Patients After Complete or Partial Response to Induction Chemotherapy With or Without Radiation Therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":196,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Vandetanib; Medicine; Internal medicine; Placebo; Gastroenterology; Oncology; Cancer; Phases of clinical research; Chemotherapy; Surgery; Pathology; Sorafenib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.02533067,0.0002573171,0.002976155,0.0003577239,0.00008141948,0.000007648467,0.0002267897,0.0002252886,0.0002631452],"category_scores_gemma":[0.01004469,0.0001384628,0.0001856161,0.0006172502,0.000208965,0.0001645301,0.00007179016,0.0009513591,1.961269e-7],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001411894,"about_ca_system_score_gemma":0.01616834,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.0197544,"about_ca_topic_score_gemma":0.6925155,"domain_scores_codex":[0.9893242,0.003090169,0.00539221,0.0003986223,0.001411468,0.0003833211],"domain_scores_gemma":[0.988769,0.005703026,0.003240072,0.0002121707,0.001642205,0.000433515],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5027769,0.02059345,0.4430085,0.00003083521,0.001228239,0.0001774687,0.00171285,0.0000714317,0.0001395533,1.424959e-7,0.00120857,0.02905208],"study_design_scores_gemma":[0.18923,0.181043,0.6173336,0.0001913615,0.0003939892,0.000007609947,0.001187575,0.00008715585,0.0001004304,0.000001103045,0.01027777,0.0001464345],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9916983,0.0001928699,0.00006169825,0.0021736,0.001737076,0.004066242,0.00004566471,0.000004990225,0.00001955124],"genre_scores_gemma":[0.9961205,0.0004947144,0.0003322954,0.001233511,0.001310997,0.0001911922,0.000002569394,0.00002936597,0.0002848125],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6727611,"threshold_uncertainty_score":0.9982941,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2888795793822542,"score_gpt":0.5751775702922032,"score_spread":0.286297990909949,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}